Leading experts from the First Affiliated Hospital of Sun Yat-sen University have emphasized that the integration of standardized neoadjuvant therapy with advanced minimally invasive techniques is heralding a new era of hope for pancreatic cancer treatment, significantly enhancing the prospects of cure. Furthermore, the rapid advancement of domestic surgical robots suggests that they are on track to become a standard configuration in hepatobiliary and pancreatic surgeries within the next 5 to 10 years.